These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Ectopic lipid metabolism in anterior pituitary dysfunction. Baumgartner C; Krššák M; Vila G; Krebs M; Wolf P Front Endocrinol (Lausanne); 2023; 14():1075776. PubMed ID: 36860364 [TBL] [Abstract][Full Text] [Related]
7. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 ( Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM Elife; 2023 Aug; 12():. PubMed ID: 37580962 [TBL] [Abstract][Full Text] [Related]
8. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. Xi Y; Li H Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192 [TBL] [Abstract][Full Text] [Related]
9. Innate immune regulatory networks in hepatic lipid metabolism. Bai L; Li H J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617 [TBL] [Abstract][Full Text] [Related]
10. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism. He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994 [TBL] [Abstract][Full Text] [Related]
11. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. Liao CJ; Huang PS; Chien HT; Lin TK; Yeh CT; Lin KH Biomedicines; 2022 May; 10(6):. PubMed ID: 35740254 [TBL] [Abstract][Full Text] [Related]
13. Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease. Fröhlich E; Wahl R Metabolites; 2022 Aug; 12(8):. PubMed ID: 36005590 [TBL] [Abstract][Full Text] [Related]
14. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Sinha RA; Singh BK; Yen PM Trends Endocrinol Metab; 2014 Oct; 25(10):538-45. PubMed ID: 25127738 [TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis reveals exercise training induced remodelling of hepatokine secretion and uncovers syndecan-4 as a regulator of hepatic lipid metabolism. De Nardo W; Miotto PM; Bayliss J; Nie S; Keenan SN; Montgomery MK; Watt MJ Mol Metab; 2022 Jun; 60():101491. PubMed ID: 35381388 [TBL] [Abstract][Full Text] [Related]
17. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Cable EE; Finn PD; Stebbins JW; Hou J; Ito BR; van Poelje PD; Linemeyer DL; Erion MD Hepatology; 2009 Feb; 49(2):407-17. PubMed ID: 19072834 [TBL] [Abstract][Full Text] [Related]
18. Prolactin improves hepatic steatosis via CD36 pathway. Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209 [TBL] [Abstract][Full Text] [Related]
19. Exposure to low-intensity noise exacerbates nonalcoholic fatty liver disease by activating hypothalamus pituitary adrenal axis. Luo J; Yan Z; Shen Y; Liu D; Su M; Yang J; Xie J; Gao H; Yang J; Liu A Sci Total Environ; 2024 Jan; 906():167395. PubMed ID: 37774888 [TBL] [Abstract][Full Text] [Related]
20. Models of non-Alcoholic Fatty Liver Disease and Potential Translational Value: the Effects of 3,5-L-diiodothyronine. Grasselli E; Canesi L; Portincasa P; Voci A; Vergani L; Demori I Ann Hepatol; 2017; 16(5):707-719. PubMed ID: 28809727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]